StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Padcev (enfortumab vedotin ADC by Quarter

Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Padcev (enfortumab vedotin ADC: $648M in Q2 2026, up 21.3% from a year earlier. That is the highest of the 11 quarters on record here.

Latest, Q2 2026
648
Period ended Jun 28, 2026
Change on a year earlier
+21.3%
534 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
7
Documents cited below

Where the Q2 2026 figure comes from

“|| Padcev | 667 | 542 | 23% | 23% | 648 | 534 | 21% | 19 | 7 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPadcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026648+21.3%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026585+39.6%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025500+15.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025449+10.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025534+38.0%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025419+25.4%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024433+717.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024407–Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024387–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024334–Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202353–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗

Breakdown

What makes up padcev (enfortumab vedotin ADC

Cite this data

StockData. (2026). Pfizer Padcev (enfortumab vedotin ADC ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/padcev-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.